Seaport Therapeutics (SPTX) vs. Its Rivals Head-To-Head Review

Seaport Therapeutics (NASDAQ:SPTX) is one of 907 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Seaport Therapeutics to related companies based on the strength of its earnings, dividends, analyst recommendations, valuation, profitability, institutional ownership and risk.

Profitability

This table compares Seaport Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Seaport Therapeutics Competitors	-2,324.62%	-215.62%	-16.81%

Institutional and Insider Ownership

32.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 14.0% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Seaport Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Seaport Therapeutics	N/A	-$74.88 million	-2.30
Seaport Therapeutics Competitors	$3.53 billion	$3.12 billion	536.76

Seaport Therapeutics’ peers have higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Seaport Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2	3	5	0	2.30
Seaport Therapeutics Competitors	7634	13739	25648	1003	2.42

Seaport Therapeutics currently has a consensus target price of $38.40, indicating a potential upside of 61.55%. As a group, “Pharmaceuticals” companies have a potential upside of 31.37%. Given Seaport Therapeutics’ higher probable upside, analysts plainly believe Seaport Therapeutics is more favorable than its peers.

Summary

Seaport Therapeutics peers beat Seaport Therapeutics on 8 of the 12 factors compared.

Seaport Therapeutics Company Profile

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.